Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s):  MYCOF

Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Comment by Momentum11on Mar 02, 2017 10:54am
66 Views
Post# 25919191

RE:RE:RE:RE:RE:RE:RE:RE:RE:SWEET NEWS !!!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:SWEET NEWS !!!!New Age Farm intends to spin out NHS as a separate operating company for a number of reasons that include, but are not limited to, the ability to list NHS on a stock exchange to build greater shareholder value in the Companys Canadian assets; to allow the Company to focus its attention on its US cannabis facilities operations which are now in production; to build a Canadian facility that is ready to take advantage of the upcoming changes to Canadian legislation regarding recreational marijuana and to provide our shareholders with the opportunity to take part in two separate and distinct companies, both with the potential to generate substantial returns that shareholders will realize from two successful operations that provide services and facilities for tenant-growers in the lucrative and growing recreational marijuana industry. Read more at https://www.stockhouse.com/news/press-releases/2016/12/05/new-age-farm-provides-update-regarding-the-plan-of-arrangement-with-nhs#REJ8XYVl14EhUcDR.99
Bullboard Posts